0000000000014242

AUTHOR

Concetta Zito

showing 27 related works from this author

Corrigendum to Patterns of ascending aortic dilatation and predictors of surgical replacement of the aorta: A comparison of bicuspid and tricuspid ao…

2020

The authors regret that the author name of Romano and Raffa are incorrect. The corrected author's name are Romano G and Raffa GM. The authors would like to apologise for any inconvenience caused.

Aortic dilatationAortic valveAortamedicine.medical_specialtybusiness.industrySettore ING-IND/34 - Bioingegneria Industrialeaorta bicuspid aortic valvemedicine.anatomical_structuremedicine.arteryInternal medicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessMolecular Biology
researchProduct

Cardioprotection by gene therapy

2015

Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprote…

Cardioprotectionmedicine.medical_specialtybiologybusiness.industryGene targetingSphingosine kinase 1Heat shock proteinInternal medicineGene expressionmedicinebiology.proteinCardiologyHepatocyte growth factorSignal transductionCardiology and Cardiovascular MedicinebusinessTranscription factormedicine.drugInternational Journal of Cardiology
researchProduct

Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome

2022

ObjectiveThe advantage of beta-blockers has been postulated in patients with Takotsubo syndrome (TTS) given the pathophysiological role of catecholamines. We hypothesised that beta-blocker treatment after discharge may improve the long-term clinical outcome in this patient population.MethodsThis was an observational, multicentre study including consecutive patients with TTS diagnosis prospectively enrolled in the Takotsubo Italian Network (TIN) register from January 2007 to December 2018. TTS was diagnosed according to the TIN, Heart Failure Association and InterTAK Diagnostic Criteria. The primary study outcome was the occurrence of all-cause death at the longest available follow-up; secon…

MaleOutcome AssessmentAdrenergic beta-AntagonistsShockCardiogenicHealth CareTinTakotsubo CardiomyopathyHypertensionOutcome Assessment Health CareHumansFemaleCardiomyopathiesCardiology and Cardiovascular MedicineCardiomyopathies; Hypertension; Outcome Assessment Health Care; Adrenergic beta-Antagonists; Aged; Female; Humans; Male; Shock Cardiogenic; Tin; Hypertension; Takotsubo CardiomyopathyAgedHeart
researchProduct

Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxici…

2020

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases. In addition, several studies indicate that MetS correlates with the increased risk of cancer in adults. The mechanisms linking MetS and cancer are not fully understood. Several risk factors involved in MetS are also cancer risk factors, such as the consumption of high calorie-food or high fat intake, low fibre intake, and sedentary lifestyle. Other common aspects of both cancer and MetS are oxidative stress and inflammation. In addition, some anticancer treatments can induce cardiotoxicity, including, for instance, left ventricular (LV) dysfunction and heart failure (HF), endothelial dysfunction an…

Oncologymedicine.medical_specialtyPhysiologyClinical BiochemistryReview030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineAgeing; Cancer; Cardiovascular disease; Cardiovascular toxicity from anticancer drugs; Metabolic syndromemedicineEndothelial dysfunctionRisk factorMolecular BiologySedentary lifestyleCancerCardiotoxicitybusiness.industrylcsh:RM1-950CancerCell Biologymedicine.diseaseCardiovascular diseaseMetabolic syndromeAgeingCardiovascular toxicity from anticancer drugslcsh:Therapeutics. PharmacologyCardiovascular toxicity from anticancer drug030220 oncology & carcinogenesisHeart failureMetabolic syndromebusinessOxidative stress
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: Role of echocardiography

2016

The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last several years. The use of drugs for the treatment of cancers increased, and new molecules and protocols were developed to improve outcomes in these patients. Although, these novel approaches also produced a progressive increase in side effects, particularly myocardial dysfunction. Imaging of the heart was highly accurate in the early diagnosis of cancer therapeutics related-cardiac dysfunction. Echocardiography is the first-line method to assess ventricular function alterations, and it is required to satisfy the need for an early, easy and accurate diagnosis to stratify the risk of heart fai…

Cardiac function curvemedicine.medical_specialtymedicine.medical_treatmentLeftEchocardiography Three-DimensionalcardiotoxicityAntineoplastic Agents030204 cardiovascular system & hematologychemotherapycancer cardiotoxicity chemotherapy echocardiographyVentricular Function Left03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsmedicinecancerHumansVentricular FunctionHeart FailureCardiotoxicityChemotherapyVentricular functionbusiness.industryCancerHeartGeneral Medicinemedicine.diseaseEchocardiography Doppler Colorcancer; cardiotoxicity; chemotherapy; echocardiography; Antineoplastic Agents; Cardiotoxicity; Heart; Heart Failure; Humans; Neoplasms; Ventricular Function Left; Early Diagnosis; Echocardiography Three-Dimensionalcancer; cardiotoxicity; echocardiographyEarly DiagnosisCardiovascular DiseasesEchocardiography030220 oncology & carcinogenesisHeart failureThree-DimensionalCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug …

2016

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to th…

cardio-oncologymedicine.medical_treatmentCardiomyopathyheart failure030204 cardiovascular system & hematologyanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Anthracyclines; Antibiotics Antineoplastic; Cardiology; Cardiomyopathies; Cardiotoxicity; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Disease Managementanthracyclines; cardiotoxicity; heart failurecardiology consult0302 clinical medicineCardiologistsAntibioticsNeoplasmsDisease management (health)Societies Medicalmedia_commonanthracyclinesAntibiotics AntineoplasticDisease ManagementGeneral MedicineAntineoplasticItalyCardiovascular Diseases030220 oncology & carcinogenesisSupplement SubmissionPractice Guidelines as TopicCardiologyCardiomyopathiesRisk assessmentCardiology and Cardiovascular MedicineDrugmedicine.medical_specialtyAnthracyclinemedia_common.quotation_subjectCardiologycardiotoxicityanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Cardiology and Cardiovascular MedicineAntineoplastic AgentsanthracyclineRisk Assessment03 medical and health sciencesMedicalInternal medicinemedicineHumansIntensive care medicineCardiotoxicityChemotherapybusiness.industrymedicine.diseaseHeart failureSocietiesbusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Independent Impact of RV Involvement on In-Hospital Outcome of Patients With Takotsubo Syndrome

2016

Takotsubo syndrome (TTS) is an acute clinical condition characterized by transient left ventricular dysfunction and reversible heart failure, the pathogenetic mechanism of which remains unclear. Although left ventricular apical ballooning is the most frequent morphological pattern, other variant forms have been described (1). In addition, right ventricular involvement (RVi), characterized by the presence of right ventricular (RV) apical dysfunction (biventricular ballooning), has been documented using echocardiography or cardiac magnetic resonance imaging. However, the prevalence, clinical profile, and in-hospital course of TTS patients with RVi are still not well defined. To date, although…

Malemedicine.medical_specialtyCoronary Artery SpasmShock Cardiogenic030204 cardiovascular system & hematologyTakotsubo Cardiomyopathy Cardiogenic Shock Coronary Artery SpasmVentricular Function Left03 medical and health sciences0302 clinical medicineText miningPredictive Value of TestsRisk FactorsTakotsubo CardiomyopathyInternal medicineNuclear Medicine and ImagingmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineHospital MortalityProspective StudiesAgedAged 80 and overCardiogenic ShockTakotsubo syndromeApical ballooningMechanism (biology)business.industryTakotsubo SyndromeRadiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineMiddle Agedmedicine.diseasePrognosisHospitalizationHospital outcomesEchocardiographyHeart failureCardiologyVentricular Function RightFemalebusinessRadiologyCardiology and Cardiovascular Medicine
researchProduct

Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction

2019

Aim: To evaluate the long-term outcome of patients with Takotsubo syndrome (TTS) and severely reduced left ventricular ejection fraction (LVEF ≤ 35%) at presentation. Methods and results: The study population included 326 patients (mean age 69.5 ± 10.7 years, 28 male) with TTS enrolled in the Takotsubo Italian Network, divided into two groups according to LVEF (≤ 35%, n = 131; > 35%, n = 195), as assessed by transthoracic echocardiography at hospital admission. In-hospital events were recorded in both groups. At long-term follow-up (median 26.5 months, interquartile range 18–33), composite major adverse cardiac events (MACE: cardiac death, acute myocardial infarction, heart failure, and …

medicine.medical_specialtyLeft ventricular ejection fractionCardiomyopathyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecardiovascular diseasesMyocardial infarctionCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndromeCardiogenic shockEjection fractionbusiness.industryCardiogenic shockHazard ratiomedicine.diseaseConfidence intervalHeart failureCardiologybusinessTakotsubo syndromeCardiology and Cardiovascular MedicineCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndrome; Cardiology and Cardiovascular MedicineMace
researchProduct

Evaluation of atrial function by 2D strain echocardiography in patients with atrial fibrillation

2012

Abstract Objectives To evaluate atrial function by 2D strain in patients with atrial fibrillation (AF) and normal or slightly increased atrial size and to verify whether lower atrial strain is associated with more frequent AF recurrences. Materials and methods We studied 50 patients with AF, mean age 59.6 ± 13 years and 50 age-and gender-matched controls. We analyzed left atrial function through 2Dstrain imaging, after the re-establishment of sinus rhythm (SR) and we investigated about the recurrences of the arrhythmia. Results Atrial strain (AS) was lower in AF patients vs controls (LA p Conclusions The assessment of atrial function by strain imaging might help to identify patients who nee…

medicine.medical_specialtyPopulationLeft atrialRecurrenceInternal medicineAtrial strainNuclear Medicine and ImagingmedicineRadiology Nuclear Medicine and imagingSinus rhythmIn patientcardiovascular diseaseseducation2d strainSinus rhythmeducation.field_of_study2D strain; Atrial fibrillation; Atrial strain; Recurrence; Sinus rhythm; Cardiology and Cardiovascular Medicine; Radiology Nuclear Medicine and Imagingbusiness.industryP wave2D strainAtrial fibrillationmedicine.diseaseAtrial fibrillationAtrial straincardiovascular systemCardiologybusinessCardiology and Cardiovascular MedicineRadiology
researchProduct

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardioto…

2015

Although treatment for heart failure induced by cancer therapy has improved in recent years, the prevalence of cardiomyopathy due to antineoplastic therapy remains significant worldwide. In addition to traditional mediators of myocardial damage, such as reactive oxygen species, new pathways and target cells should be considered responsible for the impairment of cardiac function during anticancer treatment. Accordingly, there is a need to develop novel therapeutic strategies to protect the heart from pharmacologic injury, and improve clinical outcomes in cancer patients. The development of novel protective therapies requires testing putative therapeutic strategies in appropriate animal model…

Cardiac function curveACE inhibitorsCardiotonic AgentsNeuregulin-1CardiomyopathyAntineoplastic AgentsPreclinical modelsCardioprotectionCardiotonic AgentsPharmacologyBioinformaticsmedicine.disease_causeCancer therapy-induced cardiac injury ;Preclinical modelsMitochondria HeartBeta-blockersNeoplasmsCancer therapy-induced cardiac injuryMedicineAnimalsHumansCardiac stem cellsCardioprotectionCardiotoxicityACE inhibitors; Beta-blockers; Cancer therapy-induced cardiac injury; Cardiac stem cells; Cardioprotection; Mitochondria; Neuregulin-1; Oxidative stress; Preclinical models; Statinsbusiness.industryStatinsCancermedicine.diseaseCardiotoxicityMitochondriaCancer therapy-induced cardiac injury Preclinical models Cardioprotection Mitochondria Neuregulin-1 Oxidative stress Statins Beta-blockers ACE inhibitors Cardiac stem cellsDisease Models AnimalOxidative StressHeart failureCardiology and Cardiovascular MedicinebusinessOxidative stress
researchProduct

Patterns of ascending aortic dilatation and predictors of surgical replacement of the aorta: A comparison of bicuspid and tricuspid aortic valve pati…

2019

Abstract Background Predictors of thoracic aorta growth and early cardiac surgery in patients with bicuspid aortic valve are undefined. Our aim was to identify predictors of ascending aorta dilatation and cardiac surgery in patients with bicuspid aortic valve (BAV). Methods Forty-one patients with BAV were compared with 165 patients with tricuspid aortic valve (TAV). All patients had LV EF > 50%, normal LV dimensions, and similar degree of aortic root or ascending aorta dilatation at enrollment. Patients with more than mild aortic stenosis or regurgitation were excluded. A CT-scan was available on 76% of the population, and an echocardiogram was repeated every year for a median time of 4 ye…

0301 basic medicineAortic valveMalemedicine.medical_specialtyBicuspid aortic valveHeart Valve Diseases030204 cardiovascular system & hematologyThoracic aorta03 medical and health sciencesAortic aneurysm0302 clinical medicineBicuspid aortic valveAneurysmBicuspid Aortic Valve DiseaseAneurysm; Bicuspid aortic valve; Echocardiography; Repeated measures; Thoracic aortaInternal medicinemedicine.arterymedicineThoracic aortaHumansMolecular BiologyAortaAgedDyslipidemiasAortaTricuspid valvebusiness.industryAortic Valve StenosisMiddle Agedmedicine.diseaseAneurysmStenosis030104 developmental biologymedicine.anatomical_structureRepeated measureEchocardiographyAortic ValveHypertensioncardiovascular systemCardiologyFemaleTricuspid ValveRepeated measuresCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedDilatation PathologicFollow-Up Studies
researchProduct

Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women

2021

Purpose: It is well known that anticancer drugs used for treating breast cancer can cause cardiac toxicity, and less is known about vascular toxicity. The aim of this study was to assess subclinical vascular effects of anthracyclines and trastuzumab (TRZ) in women treated for breast cancer.Methods: We enrolled 133 female patients with breast cancer undergoing adjuvant treatment with anthracycline-containing chemotherapy (CT) followed by taxane (paclitaxel/docetaxel) + TRZ. Patients underwent a standard echocardiography including measurement of left ventricular ejection fraction and global longitudinal strain at baseline and at follow-up. Vascular toxicity was evaluated by measuring brachial…

medicine.medical_specialtyAnthracyclinePhysiologypulse wave velocitycardiotoxicity030204 cardiovascular system & hematologychemotherapy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinePhysiology (medical)medicineQP1-981Pulse wave velocityvascular injuryOriginal ResearchTaxaneEjection fractionbusiness.industrymedicine.diseaseArterial stiffneBlood pressurearterial stiffness; cardiotoxicity; chemotherapy; pulse wave velocity; vascular injuryarterial stiffnessDocetaxel030220 oncology & carcinogenesisCardiologyArterial stiffnessbusinessmedicine.drugFrontiers in Physiology
researchProduct

5037Drug treatment with beta-blockers and long-term outcome in patients with takotsubo syndrome: results from the takotsubo Italian network

2019

Abstract Background Although generally considered a benign disease, Takotsubo syndrome (TTS) has recently been associated to a substantially comparable long-term outcome than acute coronary syndrome (ACS). The use of beta-blockers (BB) has been advocated in these patients for secondary prevention after the index event, considering the presumed role of catecholamine in TTS pathophysiology. However, the effect of BB on long-term outcome remains controversial due to the paucity of data and the lack of evidence from randomized studies. Purpose To investigate the impact of BB therapy on long-term outcome in patients with TTS. Methods The study included all TTS patients enrolled in the Takotsubo …

medicine.medical_specialtyTakotsubo syndromebusiness.industrymedicine.diseaseTerm (time)PharmacotherapyHeart failureInternal medicinemedicineCardiologyIn patientCardiology and Cardiovascular MedicineBeta (finance)businessEuropean Heart Journal
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Multimodalities imaging in diagnosis of pericardial cyst

2015

Pericardial cysts, an uncommon benign congenital anomaly belonging to the category of mediastinal masses. Cysts are usually detected incidentally on chest radiography or echocardiography, being most patients asymptomatic. In some cases, however, symptoms and complications occur, like dyspnea, chest pain, or persistent cough. Computed tomography and magnetic resonance imaging are the imaging techniques of choice to diagnose pericardial cysts. The removal of pericardial cysts is restricted to the cases with an uncertain diagnosis or in the presence of symptoms.

medicine.medical_specialtyCardiac magnetic resonancemedicine.diagnostic_testbusiness.industrymediastinal tumorRadiographyMediastinal tumorCase ReportMagnetic resonance imagingChest painmedicine.diseaseAsymptomaticCardiac magnetic resonance mediastinal tumor pericardial cystSurgerypericardial cystUncertain diagnosisparasitic diseasesmedicinePersistent coughRadiology Nuclear Medicine and imagingRadiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessPericardial cystJournal of Cardiovascular Echography
researchProduct

Role of biomarkers in monitoring antiblastic cardiotoxicity

2016

Early detection of anticancer drug-induced cardiotoxicity (CTX) has been evaluated by most international scientific cardiology and oncology societies. High expectations have been placed on the use of specific biomarkers. In recent years, conventional biomarkers and molecules of more recent interest have been tested and compared in the context of anticancer drug-related CTX. Encouraging results were obtained from studies on molecules of myocardial damage, such as troponin and markers of myocardial wall stress, including circulating natriuretic peptides, as well as from the assessment of the products of inflammation or circulating levels of free radicals. However, clear guidelines on their se…

cardiac toxicitymedicine.medical_specialtyantiblasticantineoplasticEarly detectionContext (language use)Antineoplastic Agentsantiblastic; anticancer drugs; antineoplastic; biomarkers; brain natriuretic peptide; cardiac toxicity; troponin; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyBioinformaticsbrain natriuretic peptideSensitivity and Specificity03 medical and health sciencesWall stress0302 clinical medicineCardiac toxicityNeoplasmsNatriuretic Peptide BrainmedicineHumansanticancer drugIntensive care medicineantineoplastic antiblastic anticancer drugs biomarkers brain natriuretic peptide cardiac toxicity troponinMonitoring PhysiologicCardiotoxicitybusiness.industrytroponinbiomarkersGeneral MedicineTime optimalCardiotoxicityanticancer drugsEarly DiagnosisCardiovascular Diseases030220 oncology & carcinogenesisbiomarkerbusinessCardiology and Cardiovascular Medicine
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond

2017

Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemotherapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT interval prolongation and arrhythmias. Currently, a field of intense research is the vascular toxicity induced by new biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) and other tyrosine kinases.…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentVascular toxicity VEGF cardiotoxicity new target therapy chemotherapy radiotherapy cardio-oncologyAntineoplastic Agents030204 cardiovascular system & hematologyQT intervalCardiooncology03 medical and health scienceschemistry.chemical_compoundCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Medicine (all); Cardiology and Cardiovascular Medicine0302 clinical medicineVascularReceptorsmedicineAnimalsHumansChemotherapyEndotheliumNew target therapyChemotherapyCardiotoxicityRadiotherapybusiness.industryVascular Endothelial Growth FactorMedicine (all)Cardiooncology; Vascular toxicity; New target therapyCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Animals; Antineoplastic Agents; Cardiotoxicity; Endothelium Vascular; Heart Diseases; Humans; Reactive Oxygen Species; Receptors Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Amedicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorRadiation therapyCardio-oncologyVascular endothelial growth factor AReceptors Vascular Endothelial Growth Factorchemistry030220 oncology & carcinogenesisHeart failureCancer researchEndothelium VascularVascular toxicityReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessTyrosine kinaseInternational Journal of Cardiology
researchProduct

Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study

2019

International audience; Aims - To obtain the normal ranges for 2D echocardiographic (2DE) indices of myocardial work (MW) from a large group of healthy volunteers over a wide range of ages and gender. Methods and results - A total of 226 (85 men, mean age: 45 ± 13 years) healthy subjects were enrolled at 22 collaborating institutions of the Normal Reference Ranges for Echocardiography (NORRE) study. Global work index (GWI), global constructive work (GCW), global work waste (GWW), and global work efficiency (GWE) were estimated from left ventricle (LV) pressure-strain loops. Peak LV systolic pressure was non-invasively derived from brachial artery cuff pressure. The lowest values of MW indic…

Malemedicine.medical_specialtyadult echocardiographyWork efficiency030204 cardiovascular system & hematology2D echocardiography03 medical and health sciences0302 clinical medicineReference ValuesInternal medicinemedicine.arteryHealthy volunteersMedicineHumansRadiology Nuclear Medicine and imaging2D echocardiography; adult echocardiography; myocardial work; reference values.Prospective StudiesBrachial arteryadult echocardiography • 2D echocardiography • myocardial work • reference valuesbusiness.industryNon invasiveHealthy subjectsreference valueMean ageGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREMiddle Agedmyocardial workEuropeBlood pressureEchocardiographyHeart Function TestsCardiologyFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringCardiology and Cardiovascular MedicinebusinessLarge group[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing
researchProduct

Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

2018

Antineoplastic drugs can be associated with several side effects, including cardiovascular toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX. Chemoterapeutic agents can alter redox homeostasis by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species RNS. Cellular sources of ROS/RNS are cardiomyocytes, endothelial cells, stromal and inflammatory cells in the heart. Mitochondria, peroxisomes and other subcellular components are central hubs that control redox homeostasis. Mitochondria are central targets for antineoplastic drug-induced CTX. Understanding the mechanisms of CTX is fundamental for effective cardioprotection, without…

Stromal cellPhysiologymedicine.medical_treatmentTyrosine kinase inhibitorChemotherapy; HER-2 inhibitors; Oxidative/nitrosative stress; Tyrosine kinase inhibitors; Vascular endothelial growth factorReviewOxidative phosphorylation030204 cardiovascular system & hematologyMitochondrionPharmacologyChemotherapy; HER-2 inhibitors; Oxidative/nitrosative stress; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Physiology; Physiology (medical)chemotherapyHER-2 inhibitorlcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)tyrosine kinase inhibitorsMedicinechemotherapy HER-2 inhibitors oxidative/nitrosative stress vascular endothelial growth factor tyrosine kinase inhibitorsReactive nitrogen specieschemistry.chemical_classificationCardioprotectionReactive oxygen speciesChemotherapyCardiotoxicitylcsh:QP1-981vascular endothelial growth factorbusiness.industryOxidative/nitrosative strechemistry030220 oncology & carcinogenesisbusinessHER-2 inhibitorsoxidative/nitrosative stress
researchProduct

Association Between Carotid Atherosclerosis and Metabolic Syndrome: Results From the ISMIR Study

2010

The metabolic syndrome (MetS) has previously been associated with an early marker of atherosclerosis, the carotid intima-media thickness (IMT). From the ISMIR (Ispessimento Medio Intimale e Rischio cardiovascolare [media-intima thickness and cardiovascular risk]) study population of 479 asymptomatic participants, we identified 80 participants with MetS. Carotid IMT and plaques were evaluated by ultrasonography. Blood samples were obtained from all participants. Participants with MetS had a significantly higher prevalence of a carotid IMT > 0.80 mm (P = .004) and of carotid plaques (P < .001) as compared with participants without MetS. Carotid IMT was significantly correlated with fas…

Blood GlucoseCarotid Artery DiseasesMalemedicine.medical_specialtycarotid intima-media thickness; carotid plaques; fibrinogen; metabolic syndrome; triglyceridescarotid intima-media thicknessFibrinogenAsymptomaticchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesTriglyceridesAgedMetabolic SyndromeCreatinineVascular diseasebusiness.industrycarotid plaquesFibrinogenMiddle Agedmedicine.diseaseUric AcidCross-Sectional Studiesmedicine.anatomical_structureEndocrinologyItalychemistryCreatininecardiovascular systemCardiologyUric acidPopulation studyFemalemedicine.symptomMetabolic syndromeTunica IntimaTunica MediaCardiology and Cardiovascular Medicinebusinessmedicine.drugArteryAngiology
researchProduct

Pathophysiology of anthracycline cardiotoxicity.

2016

Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to th…

DrugAnthracyclinemedia_common.quotation_subjectLeftanthracyclines; cancer; cardiotoxicity; Cardiology and Cardiovascular MedicineDose dependenceAntineoplastic Agents030204 cardiovascular system & hematologyanthracyclineBioinformatics03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineAntibioticsNeoplasmsVentricular DysfunctionmedicinecancerHumansGenetic Predisposition to DiseaseAnthracyclinesmedia_commonHeart FailureCardiotoxicityAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryanthracyclines cancer cardiotoxicityCancerHeartGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseAntineoplasticPathophysiologyCardiotoxicityCardiovascular Diseases030220 oncology & carcinogenesisHeart failureCardiology and Cardiovascular Medicinebusinessanthracyclines; cancer; cardiotoxicity; Anthracyclines; Antibiotics Antineoplastic; Cardiotoxicity; Heart Failure; Humans; Neoplasms; Ventricular Dysfunction LeftJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Correlation between non-invasive myocardial work indices and main parameters of systolic and diastolic function

2020

Abstract Aims The present study sought to evaluate the correlation between indices of non-invasive myocardial work (MW) and left ventricle (LV) size, traditional and advanced parameters of LV systolic and diastolic function by 2D echocardiography (2DE). Methods and results A total of 226 (85 men, mean age: 45 ± 13 years) healthy subjects were enrolled at 22 collaborating institutions of the Normal Reference Ranges for Echocardiography (NORRE) study. Global work index (GWI), global constructive work (GCW), global work waste (GWW), and global work efficiency (GWE) were estimated from LV pressure-strain loops using custom software. Peak LV pressure was estimated non-invasively from brachial ar…

AdultMalemedicine.medical_specialtySystoleadult echocardiographyDiastoleSpeckle tracking echocardiography030204 cardiovascular system & hematologyadult echocardiography; myocardial strain; myocardial work; speckle tracking echocardiographyVentricular Function LeftCorrelationVentricular Dysfunction Left03 medical and health sciences0302 clinical medicineDiastoleInternal medicinemedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineSystolespeckle tracking echocardiographyEjection fractionbusiness.industryWork (physics)Stroke VolumeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREGeneral MedicineMiddle Agedmyocardial workmedicine.anatomical_structureBlood pressureEchocardiographyVentriclemyocardial strainCardiology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCardiology and Cardiovascular Medicinebusiness
researchProduct

Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology

2016

Chemotherapy-induced cardiotoxicity (CTX) is a determining factor for the quality of life and mortality of patients administered potentially cardiotoxic drugs and in long-term cancer survivors. Therefore, prevention and early detection of CTX are highly desirable, as is the exploration of alternative therapeutic strategies and/or the proposal of potentially cardioprotective treatments. In recent years, cardiovascular imaging has acquired a pivotal role in this setting. Although echocardiography remains the diagnostic method most used to monitor cancer patients, the need for more reliable, reproducible and accurate detection of early chemotherapy-induced CTX has encouraged the introduction o…

medicine.medical_specialtyDiagnostic methodspositron emission tomographycardiotoxicityEarly detectionAntineoplastic Agents030204 cardiovascular system & hematologynuclear cardiologyVentricular Function Left030218 nuclear medicine & medical imagingAntineoplastic Agent03 medical and health sciencescardiovascular magnetic resonance0302 clinical medicineQuality of lifeNeoplasmsInternal medicineEarly DiagnosimedicineHumanscardiotoxicity; cardiovascular magnetic resonanceCardiotoxicitymedicine.diagnostic_testbusiness.industryMyocardiumcardiotoxicity; cardiovascular magnetic resonance; nuclear cardiology; positron emission tomography; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Humans; Neoplasms; Quality of Life; Early Diagnosis; Magnetic Resonance Imaging; Positron-Emission TomographyCancerMagnetic resonance imagingGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingOxygenEarly DiagnosisCardiovascular DiseasesPositron emission tomographyEchocardiographyPositron-Emission TomographyCardiologyQuality of Lifecardiotoxicity cardiovascular magnetic resonance nuclear cardiology positron emission tomographyNeoplasmCardiology and Cardiovascular MedicineCardiac magnetic resonancebusinessHuman
researchProduct

From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview

2019

Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated…

Cardiovascular toxicityPhysiologymedicine.medical_treatmentAntineoplastic drugClinical BiochemistryAntineoplastic Agents030204 cardiovascular system & hematologyPharmacologyBiochemistryCardiac cellcancer immunotherapy; chemotherapy; ErbB2 inhibitors; oxidative/nitrosative stress; tyrosine kinase inhibitors; vascular endothelial growth factor; Antineoplastic Agents; Cardiotoxicity; Humans; Mitochondria; Oxidation-Reduction03 medical and health scienceschemistry.chemical_compoundErbB2 inhibitors cancer immunotherapy chemotherapy oxidative/nitrosative stress tyrosine kinase inhibitors vascular endothelial growth factor0302 clinical medicinetyrosine kinase inhibitorcancer immunotherapy; chemotherapy; ErbB2 inhibitors; oxidative/nitrosative stress; tyrosine kinase inhibitors; vascular endothelial growth factorChemotherapy; ErbB2 inhibitors; vascular endothelial growth factor; tyrosine kinase inhibitors; oxidative/nitrosative stress; cancer immunotherapyCancer immunotherapytyrosine kinase inhibitorsmedicineHumansChemotherapyMolecular BiologyGeneral Environmental ScienceCardioprotectionComprehensive Invited ReviewsChemotherapyErbB2 inhibitorcancer immunotherapyvascular endothelial growth factorbusiness.industryCell BiologyCardiotoxicityMitochondriaVascular endothelial growth factoroxidative/nitrosative streErbB2 inhibitorschemistry030220 oncology & carcinogenesisGeneral Earth and Planetary SciencesbusinessOxidation-ReductionAfter treatmentoxidative/nitrosative stress
researchProduct